3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 1/2
1
Status
Completed
10
Unknown
2
Terminated
2
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Metformin
3
Letrozole
3
Sperm Injections, Intracytoplasmic
2
Progesterone
2
Lidocaine
2
Indocyanine Green
2
Gentamicins
2
Estradiol
2
Clomiphene
2
Bevacizumab
2
Acitretin
2
tirbanibulin
1
technetium Tc 99m nanocolloid
1
suvorexant
1
pomalidomide
1
pembrolizumab
1
pasireotide
1
nilotinib
1
methylnaltrexone
1
ledipasvir
1
ixazomib
1
gadolinium ethoxybenzyl DTPA
1
gadofosveset trisodium
1
exemestane
1
encorafenib
1
dolutegravir
1
ceftolozane, tazobactam drug combination
1
binimetinib
1
bicalutamide
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Withdrawn
×
nilotinib
×
Clear all
NCT01605981
2017-04-20
MACS1881
Novartis
Phase 4
Withdrawn